BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. JAMA Oncol. 2017;3:767-773. [PMID: 27737436 DOI: 10.1001/jamaoncol.2016.3358] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-ribeiro AB, Xavier CP, Vasconcelos MH. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resistance Updates 2019;46:100645. [DOI: 10.1016/j.drup.2019.100645] [Cited by in Crossref: 81] [Cited by in F6Publishing: 80] [Article Influence: 27.0] [Reference Citation Analysis]
2 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
3 Harguindey S, Stanciu D, Devesa J, Alfarouk K, Cardone RA, Polo Orozco JD, Devesa P, Rauch C, Orive G, Anitua E, Roger S, Reshkin SJ. Cellular acidification as a new approach to cancer treatment and to the understanding and therapeutics of neurodegenerative diseases. Semin Cancer Biol 2017;43:157-79. [PMID: 28193528 DOI: 10.1016/j.semcancer.2017.02.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
4 Song HJ, Rhew K, Lee YJ, Ha IH. Acid-suppressive agents and survival outcomes in patients with cancer: a systematic review and meta-analysis. Int J Clin Oncol 2021;26:34-50. [PMID: 33089416 DOI: 10.1007/s10147-020-01795-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Menon A, Abraham AG, Mahfouz M, Thachuthara JJ, Usmani N, Warkentin H, Ghosh S, Nijjar T, Severin D, Tankel K, Paulson K, Mulder K, Roa W, Joseph K. Concomitant Use of Proton Pump Inhibitors With Capecitabine Based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: Is it Safe? Am J Clin Oncol 2021;44:487-94. [PMID: 34269694 DOI: 10.1097/COC.0000000000000850] [Reference Citation Analysis]
6 Zaanan A, Bouché O, Benhaim L, Buecher B, Chapelle N, Dubreuil O, Fares N, Granger V, Lefort C, Gagniere J, Meilleroux J, Baumann AS, Vendrely V, Ducreux M, Michel P; Thésaurus National de Cancérologie Digestive (TNCD). Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis 2018;50:768-79. [PMID: 29886081 DOI: 10.1016/j.dld.2018.04.025] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
7 Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: Understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14:697-710. [PMID: 28930292 DOI: 10.1038/nrgastro.2017.117] [Cited by in Crossref: 96] [Cited by in F6Publishing: 72] [Article Influence: 19.2] [Reference Citation Analysis]
8 Kolosenko I, Avnet S, Baldini N, Viklund J, De Milito A. Therapeutic implications of tumor interstitial acidification. Semin Cancer Biol 2017;43:119-33. [PMID: 28188829 DOI: 10.1016/j.semcancer.2017.01.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
9 Vinarov Z, Abdallah M, Agundez JAG, Allegaert K, Basit AW, Braeckmans M, Ceulemans J, Corsetti M, Griffin BT, Grimm M, Keszthelyi D, Koziolek M, Madla CM, Matthys C, McCoubrey LE, Mitra A, Reppas C, Stappaerts J, Steenackers N, Trevaskis NL, Vanuytsel T, Vertzoni M, Weitschies W, Wilson C, Augustijns P. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. Eur J Pharm Sci 2021;162:105812. [PMID: 33753215 DOI: 10.1016/j.ejps.2021.105812] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
10 Baxter MA, Petty RD, Swinson D, Hall PS, O'Hanlon S. Real‑world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review). Int J Oncol 2021;58:22. [PMID: 33760115 DOI: 10.3892/ijo.2021.5202] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Sharma M, Vadhariya A, Chikermane S, Gopinathan S, Chavez-macgregor M, Giordano SH, Johnson ML, Holmes HM. Clinical Outcomes Associated with Drug–Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based Literature Review. Drugs Aging 2019;36:341-54. [DOI: 10.1007/s40266-019-00640-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
12 Cheng V, Lemos MD, Hunter N, Badry N, Lemos JD. Concomitant use of capecitabine and proton pump inhibitors – Is it safe? J Oncol Pharm Pract 2019;25:1705-11. [DOI: 10.1177/1078155219846952] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U, Danesi R. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open 2021;6:100231. [PMID: 34509802 DOI: 10.1016/j.esmoop.2021.100231] [Reference Citation Analysis]
14 Whitman A, DeGregory K, Morris A, Mohile S, Ramsdale E. Pharmacist-led medication assessment and deprescribing intervention for older adults with cancer and polypharmacy: a pilot study. Support Care Cancer 2018;26:4105-13. [PMID: 29869294 DOI: 10.1007/s00520-018-4281-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 9.8] [Reference Citation Analysis]
15 Hiromoto S, Kawashiri T, Yamanaka N, Kobayashi D, Mine K, Inoue M, Uchida M, Shimazoe T. Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome. Sci Rep 2021;11:8964. [PMID: 33903667 DOI: 10.1038/s41598-021-88460-9] [Reference Citation Analysis]
16 Chivu-Economescu M, Matei L, Necula LG, Dragu DL, Bleotu C, Diaconu CC. New therapeutic options opened by the molecular classification of gastric cancer. World J Gastroenterol 2018; 24(18): 1942-1961 [PMID: 29760539 DOI: 10.3748/wjg.v24.i18.1942] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
17 Baxter MA, Marinho J, Soto-Perez-de-Celis E, Rodriquenz MG, Arora SP, Lok WCW, Shih YY, Liposits G, O'Hanlon S, Petty RD. Gastroesophageal adenocarcinoma in older adults: A comprehensive narrative review of management by the young international society of geriatric oncology. J Geriatr Oncol 2021:S1879-4068(21)00207-1. [PMID: 34548259 DOI: 10.1016/j.jgo.2021.09.006] [Reference Citation Analysis]
18 van Doorn L, Heersche N, de Man FM, de Bruijn P, Bijl I, Oomen-de Hoop E, Eskens FALM, van der Gaast A, Mathijssen RHJ, Bins S. Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial. Clin Pharmacol Ther 2021. [PMID: 34656072 DOI: 10.1002/cpt.2444] [Reference Citation Analysis]
19 Wong GG, Ha V, Chu MP, Dersch-Mills D, Ghosh S, Chambers CR, Sawyer MB. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer. Clin Colorectal Cancer 2019;18:72-9. [PMID: 30551953 DOI: 10.1016/j.clcc.2018.11.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
20 Rogers JE, Eng C. Pharmacotherapeutic considerations for elderly patients with colorectal cancer. Expert Opin Pharmacother 2019;20:2139-60. [PMID: 31456458 DOI: 10.1080/14656566.2019.1657826] [Reference Citation Analysis]
21 Rhinehart HE, Phillips MA, Wade N, Baran A. Evaluation of the clinical impact of concomitant acid suppression therapy in colorectal cancer patients treated with capecitabine monotherapy. J Oncol Pharm Pract 2019;25:1839-45. [DOI: 10.1177/1078155218818237] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Lunar N, Etienne-Grimaldi MC, Macaire P, Thomas F, Dalenc F, Ferrero JM, Pivot X, Milano G, Royer B, Schmitt A. Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients. Cancer Chemother Pharmacol 2021;87:229-39. [PMID: 33386926 DOI: 10.1007/s00280-020-04208-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kim SY, Lee JS, Kang J, Morita S, Park YS, Sakamoto J, Muro K, Xu RH, Kim TW. Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT). Oncologist 2021;26:e954-62. [PMID: 33644953 DOI: 10.1002/onco.13735] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Rogala BG, Charpentier MM, Nguyen MK, Landolf KM, Hamad L, Gaertner KM. Oral Anticancer Therapy: Management of Drug Interactions. J Oncol Pract 2019;15:81-90. [PMID: 30763198 DOI: 10.1200/JOP.18.00483] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
25 Meriggi F. Controversial link between proton pump inhibitors and anticancer agents: review of the literature. Tumori 2021;:3008916211025091. [PMID: 34159850 DOI: 10.1177/03008916211025091] [Reference Citation Analysis]
26 Schubert ML. Adverse effects of proton pump inhibitors: fact or fake news? Current Opinion in Gastroenterology 2018;34:451-7. [DOI: 10.1097/mog.0000000000000471] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
27 Raoul JL, Guérin-Charbonnel C, Edeline J, Simmet V, Gilabert M, Frenel JS. Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer. JAMA Netw Open 2021;4:e2113739. [PMID: 34132796 DOI: 10.1001/jamanetworkopen.2021.13739] [Reference Citation Analysis]
28 Sekido M, Fujita K, Kubota Y, Ishida H, Takahashi T, Ohkuma R, Tsunoda T, Ishikawa F, Shibanuma M, Sasaki Y. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil. Cancer Chemother Pharmacol 2019;83:1127-35. [DOI: 10.1007/s00280-019-03837-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
29 . Incorrect Percentages in the Abstract. JAMA Oncol 2017;3:1742. [PMID: 29145564 DOI: 10.1001/jamaoncol.2017.4368] [Reference Citation Analysis]
30 Satake H, Yasui H, Kotake T, Okita Y, Hatachi Y, Kotaka M, Kato T, Tsuji A. First-line chemotherapy with capecitabine/oxaliplatin for advanced gastric cancer: A phase I study. Mol Clin Oncol 2017;7:347-50. [PMID: 28894576 DOI: 10.3892/mco.2017.1335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
31 Wang X, Liu Q, Halfdanarson ÓÖ, Zoega H, Sadr-Azodi O, Engstrand L, Fall K, Brusselaers N. Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study. Br J Cancer 2021. [PMID: 34253872 DOI: 10.1038/s41416-021-01480-0] [Reference Citation Analysis]
32 Ning FL, Zhang NN, Wang J, Jin YF, Quan HG, Pei JP, Zhao Y, Zeng XT, Abe M, Zhang CD. Prognostic value of modified Lauren classification in gastric cancer. World J Gastrointest Oncol 2021; 13(9): 1184-1195 [PMID: 34616522 DOI: 10.4251/wjgo.v13.i9.1184] [Reference Citation Analysis]
33 Indini A, Petrelli F, Tomasello G, Rijavec E, Facciorusso A, Grossi F, Ghidini M. Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. Cancers (Basel). 2020;12. [PMID: 32325628 DOI: 10.3390/cancers12040998] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
34 Granja S, Tavares-Valente D, Queirós O, Baltazar F. Value of pH regulators in the diagnosis, prognosis and treatment of cancer. Semin Cancer Biol 2017;43:17-34. [PMID: 28065864 DOI: 10.1016/j.semcancer.2016.12.003] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
35 Song W, Shi L, Wang Y, Zhang Z. Proton pump inhibitors and increased reporting odds of renal neoplasms: FAERS-based adverse event data mining and analysis. Expert Opin Drug Saf 2021;:1-7. [PMID: 34915780 DOI: 10.1080/14740338.2022.2020245] [Reference Citation Analysis]
36 Uchiyama AAT, Silva PAIA, Lopes MSM, Yen CT, Ricardo ED, Mutão T, Pimenta JR, Machado LM, Shimba DS, Peixoto RD. Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists. Curr Oncol 2021;28:783-99. [PMID: 33546228 DOI: 10.3390/curroncol28010076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
37 Elias E, Targownik LE. The Clinician's Guide to Proton Pump Inhibitor Related Adverse Events. Drugs 2019;79:715-31. [PMID: 30972661 DOI: 10.1007/s40265-019-01110-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
38 Riechelmann RP, Krzyzanowska MK. Drug interactions and oncological outcomes: a hidden adversary. Ecancermedicalscience 2019;13:ed88. [PMID: 31123502 DOI: 10.3332/ecancer.2019.ed88] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
39 Raoul JL, Edeline J, Gilabert M, Senellart H, Frenel JS. [Proton pump inhibitors and cancers: A hazardous association?]. Bull Cancer 2020;107:458-64. [PMID: 32057465 DOI: 10.1016/j.bulcan.2019.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Sim W, Jain SR, Lim WH, Chin YH, Ng CH, Syn N, Goh KS, Soo R, Wang L, Goh BC. Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res 2021;10:3567-81. [PMID: 34584857 DOI: 10.21037/tlcr-21-378] [Reference Citation Analysis]